肺心胶囊治疗肺心病30例临床疗效观察

CLINICAL OBSERVATION OF FEI-XIN CAPSULE(FXC) ON 30 PATIENTS WITH COR PUIMONALE(CCP)

为观察肺心肺囊治疗慢性肺原性心脏病的疗效。观察了肺心胶囊治疗前后本病患者的主要临床症状、免疫球蛋白、补体C3及血、尿β-MG水平的变化情况。结果：患者治疗前血清IgA及血、尿β-MG水平明显升高，C3含量明显降低。肺心胶囊治疗后治疗组血清IgA水平明显降低（P＜0.01），C3含量明显升高（P＜0.01）。说明以“补肺纳气、健脾益肾、化痰争喘”作用立法制成的肺心胶囊具有明显改善本病患者免疫功能状态的作用，具有促进已损伤了的肾功能部份好转的作用。临床观察还显示：肺心胶囊具有明显改管本病患者咳、痰、喘、气紧、心系等主要临床症状的作用。

The authors detected the level of immunoglobulin, C3 and β-MG in serum and urina from 30 patients with CCP before and after FXC treatment. The results showed that the level of IgA and β2-MG of patients before treatment was significantly higher, and C3 lower than that in normal control. After treatment, the level of IgA was significantly lower in the treated group (P<0. 001),so was the β2-MG (P<0.01). But C3 was significantly higher (P<0. 001). It shows that by reinforcing the lungs, invigorating the spleen, replenishing the kidneys, resolving phlegm, and subduing asthma, the immune function of patients with CCP could be improved by treatment with FXC. The kidney function could partly be improved, The clinical observation also shows that the cardinal symptoms (including cough, phlegm,asthma, palpitation, ect.)of patients with CCP could apparently be abated by treatment with FXC.